<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39489518</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1326-5377</ISSN><JournalIssue CitedMedium="Internet"><Volume>221 Suppl 9</Volume><PubDate><Year>2024</Year><Month>Nov</Month><Day>04</Day></PubDate></JournalIssue><Title>The Medical journal of Australia</Title><ISOAbbreviation>Med J Aust</ISOAbbreviation></Journal><ArticleTitle>Beyond acute infection: mechanisms underlying post-acute sequelae of COVID-19 (PASC).</ArticleTitle><Pagination><StartPage>S40</StartPage><EndPage>S48</EndPage><MedlinePgn>S40-S48</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5694/mja2.52456</ELocationID><Abstract><AbstractText>Immune dysregulation is a key aspect of post-acute sequelae of coronavirus disease 2019 (PASC), also known as long COVID, with sustained activation of immune cells, T cell exhaustion, skewed B cell profiles, and disrupted immune communication thereby resulting in autoimmune-related complications. The gut is emerging as a critical link between microbiota, metabolism and overall dysfunction, potentially sharing similarities with other chronic fatigue conditions and PASC. Immunothrombosis and neurological signalling dysfunction emphasise the complex interplay between the immune system, blood clotting, and the central nervous system in the context of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Clear research gaps in the design of PASC studies, especially in the context of longitudinal research, stand out as significant areas of concern.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). Medical Journal of Australia published by John Wiley &amp; Sons Australia, Ltd on behalf of AMPCo Pty Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Adhikari</LastName><ForeName>Anurag</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kathmandu Research Institute for Biological Sciences, Lalitpur, Nepal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maddumage</LastName><ForeName>Janesha</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eriksson</LastName><ForeName>Emily M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Annesley</LastName><ForeName>Sarah J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>La Trobe University, Melbourne, VIC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lawson</LastName><ForeName>Victoria A</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bryant</LastName><ForeName>Vanessa L</ForeName><Initials>VL</Initials><AffiliationInfo><Affiliation>Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Royal Melbourne Hospital, Melbourne, VIC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Melbourne, Melbourne, VIC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gras</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Monash University, Melbourne, VIC.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1159272</GrantID><Agency>National Health and Medical Research Council</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Med J Aust</MedlineTA><NlmUniqueID>0400714</NlmUniqueID><ISSNLinking>0025-729X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>4</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>4</Day><Hour>0</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>3</Day><Hour>20</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39489518</ArticleId><ArticleId IdType="doi">10.5694/mja2.52456</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. Post COVID&#x2010;19 condition (long COVID) [website]. WHO, 2022. https://www.who.int/europe/news&#x2010;room/fact&#x2010;sheets/item/post&#x2010;covid&#x2010;19&#x2010;condition (viewed Aug 2023).</Citation></Reference><Reference><Citation>Australian Institute of Health and Welfare. Long COVID in Australia &#x2014; a review of the literature [Cat. No. PHE 318]. Canberra: AIHW, 2022. https://www.aihw.gov.au/reports/covid&#x2010;19/long&#x2010;covid&#x2010;in&#x2010;australia&#x2010;a&#x2010;review&#x2010;of&#x2010;the&#x2010;literature/summary (viewed Aug 2024).</Citation></Reference><Reference><Citation>Woodrow M, Carey C, Ziauddeen N, et&#xa0;al. Systematic review of the prevalence of long COVID. Open Forum Infect Dis 2023; 10: ofad233.</Citation></Reference><Reference><Citation>Department of Health, Victorian Government. Victorian Experience with COVID&#x2010;19 Health Survey. https://vahi.vic.gov.au/news/conference&#x2010;wrap&#x2010;firsthand&#x2010;experiences&#x2010;drive&#x2010;efforts&#x2010;improve&#x2010;outcomes&#x2010;people&#x2010;long&#x2010;covid (viewed Aug 2023).</Citation></Reference><Reference><Citation>Ceban F, Ling S, Lui LMW, et&#xa0;al. Fatigue and cognitive impairment in post&#x2010;COVID&#x2010;19 syndrome: a systematic review and meta&#x2010;analysis. Brain Behav Immun 2022; 101: 93&#x2010;135.</Citation></Reference><Reference><Citation>Al&#x2010;Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS&#x2010;CoV&#x2010;2 infection. Nat Med 2022; 28: 1461&#x2010;1467.</Citation></Reference><Reference><Citation>World Health Organization. WHO COVID&#x2010;19 dashboard: number of COVID&#x2010;19 cases reported to WHO. https://data.who.int/dashboards/covid19/cases (viewed Oct 2023).</Citation></Reference><Reference><Citation>Mansell V, Hall Dykgraaf S, Kidd M, Goodyear&#x2010;Smith F. Long COVID and older people. Lancet Healthy Longev 2022; 3: e849&#x2010;e854.</Citation></Reference><Reference><Citation>Tsampasian V, Elghazaly H, Chattopadhyay R, et&#xa0;al. Risk factors associated with post&#x2010;COVID&#x2010;19 condition: a systematic review and meta&#x2010;analysis. JAMA Intern Med 2023; 183: 566&#x2010;580.</Citation></Reference><Reference><Citation>Department of Health and Aged Care, Australian Government. COVID&#x2010;19 reporting. https://www.health.gov.au/health&#x2010;alerts/covid&#x2010;19/weekly&#x2010;reporting (viewed Oct 2023).</Citation></Reference><Reference><Citation>Malesevic S, Sievi NA, Baumgartner P, et&#xa0;al. Impaired health&#x2010;related quality of life in long&#x2010;COVID syndrome after mild to moderate COVID&#x2010;19. Sci Rep 2023; 13: 7717.</Citation></Reference><Reference><Citation>Higgins V, Sohaei D, Diamandis EP, Prassas I. COVID&#x2010;19: from an acute to chronic disease? Potential long&#x2010;term health consequences. Crit Rev Clin Lab Sci 2021; 58: 297&#x2010;310.</Citation></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 2023; 21: 133&#x2010;146.</Citation></Reference><Reference><Citation>Peluso MJ, Deveau TM, Munter SE, et&#xa0;al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J Clin Invest 2023; 133: e163669.</Citation></Reference><Reference><Citation>Monje M, Iwasaki A. The neurobiology of long COVID. Neuron 2022; 110: 3484&#x2010;3496.</Citation></Reference><Reference><Citation>Jammoul M, Naddour J, Madi A, et&#xa0;al. Investigating the possible mechanisms of autonomic dysfunction post&#x2010;COVID&#x2010;19. Auton Neurosci 2023; 245: 103071.</Citation></Reference><Reference><Citation>Pellegrini L, Albecka A, Mallery DL, et&#xa0;al. SARS&#x2010;CoV&#x2010;2 infects the brain choroid plexus and disrupts the blood&#x2010;CSF barrier in human brain organoids. Cell Stem Cell 2020; 27: 951&#x2010;961.</Citation></Reference><Reference><Citation>Song E, Bartley CM, Chow RD, et&#xa0;al. Divergent and self&#x2010;reactive immune responses in the CNS of COVID&#x2010;19 patients with neurological symptoms. Cell Rep Med 2021; 2: 100288.</Citation></Reference><Reference><Citation>Andrews MG, Mukhtar T, Eze UC, et&#xa0;al. Tropism&#xa0;of SARS&#x2010;CoV&#x2010;2 for human cortical astrocytes. Proc Natl Acad Sci USA 2022; 119: e2122236119.</Citation></Reference><Reference><Citation>Jeong GU, Lyu J, Kim KD, et&#xa0;al. SARS&#x2010;CoV&#x2010;2 infection of microglia elicits proinflammatory activation and apoptotic cell death. Microbiol Spectr 2022; 10: e0109122.</Citation></Reference><Reference><Citation>Beckman D, Bonillas A, Diniz GB, et&#xa0;al. SARS&#x2010;CoV&#x2010;2 infects neurons and induces neuroinflammation in a non&#x2010;human primate model of COVID&#x2010;19. Cell Rep 2022; 41: 111573.</Citation></Reference><Reference><Citation>Mart&#xed;nez&#x2010;M&#xe1;rmol R, Giordano&#x2010;Santini R, Kaulich E, et&#xa0;al. SARS&#x2010;CoV&#x2010;2 infection and viral fusogens cause neuronal and glial fusion that compromises neuronal activity. Sci Adv 2023; 9: eadg2248.</Citation></Reference><Reference><Citation>Fern&#xe1;ndez&#x2010;Casta&#xf1;eda A, Lu P, Geraghty AC, et&#xa0;al. Mild respiratory COVID can cause multi&#x2010;lineage neural cell and myelin dysregulation. Cell 2022; 185: 2452&#x2010;2468.</Citation></Reference><Reference><Citation>Nieuwland JM, Nutma E, Philippens I, et&#xa0;al. Longitudinal positron emission tomography and postmortem analysis reveals widespread neuroinflammation in SARS&#x2010;CoV&#x2010;2 infected rhesus macaques. J Neuroinflammation 2023; 20: 179.</Citation></Reference><Reference><Citation>Wang EY, Mao T, Klein J, et&#xa0;al. Diverse functional autoantibodies in patients with COVID&#x2010;19. Nature 2021; 595: 283&#x2010;288.</Citation></Reference><Reference><Citation>Kong W, Montano M, Corley MJ, et&#xa0;al. Neuropilin&#x2010;1 mediates SARS&#x2010;CoV&#x2010;2 infection of astrocytes in brain organoids, inducing inflammation leading to dysfunction and death of neurons. mBio 2022; 13: e0230822.</Citation></Reference><Reference><Citation>Lavi Y, Vojdani A, Halpert G, et&#xa0;al. Dysregulated&#xa0;levels of circulating autoantibodies against neuronal and nervous system autoantigens in COVID&#x2010;19 patients. Diagnostics (Basel) 2023; 13: 687.</Citation></Reference><Reference><Citation>Garber C, Soung A, Vollmer LL, et&#xa0;al. T cells promote microglia&#x2010;mediated synaptic elimination and cognitive dysfunction during recovery from neuropathogenic flaviviruses. Nat Neurosci 2019; 22: 1276&#x2010;1288.</Citation></Reference><Reference><Citation>Hanson BA, Visvabharathy L, Ali ST, et&#xa0;al. Plasma biomarkers of neuropathogenesis in hospitalized patients with COVID&#x2010;19 and those with postacute sequelae of SARS&#x2010;CoV&#x2010;2 infection. Neurol Neuroimmunol Neuroinflamm 2022; 9: e1151.</Citation></Reference><Reference><Citation>Zhang H, Li HB, Lyu JR, et&#xa0;al. Specific ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury after 2019&#x2010;nCoV infection. Int J Infect Dis 2020; 96: 19&#x2010;24.</Citation></Reference><Reference><Citation>Lee S, Yoon GY, Myoung J, et&#xa0;al. Robust and persistent SARS&#x2010;CoV&#x2010;2 infection in the human intestinal brush border expressing cells. Emerg Microbes Infect 2020; 9: 2169&#x2010;2179.</Citation></Reference><Reference><Citation>Settanni CR, Ianiro G, Ponziani FR, et&#xa0;al. COVID&#x2010;19 as a trigger of irritable bowel syndrome: A review of potential mechanisms. World J Gastroenterol 2021; 27: 7433&#x2010;7445.</Citation></Reference><Reference><Citation>Teixeira PC, Dorneles GP, Santana Filho PC, et&#xa0;al. Increased LPS levels coexist with systemic inflammation and result in monocyte activation in severe COVID&#x2010;19 patients. Int Immunopharmacol 2021; 100: 108125.</Citation></Reference><Reference><Citation>Lau WL, Kalantar&#x2010;Zadeh K, Vaziri ND. The gut as a source of inflammation in chronic kidney disease. Nephron 2015; 130: 92&#x2010;98.</Citation></Reference><Reference><Citation>Giron LB, Peluso MJ, Ding J, et&#xa0;al. Markers of fungal translocation are elevated during post&#x2010;acute sequelae of SARS&#x2010;CoV&#x2010;2 and induce NF&#x2010;&#x3ba;B signaling. JCI Insight 2022; 7: e160989.</Citation></Reference><Reference><Citation>Schultheiss C, Willscher E, Paschold L, et&#xa0;al. The IL&#x2010;1&#x3b2;, IL&#x2010;6, and TNF cytokine triad is associated with post&#x2010;acute sequelae of COVID&#x2010;19. Cell Rep Med 2022; 3: 100663.</Citation></Reference><Reference><Citation>Hobby GP, Karaduta O, Dusio GF, et&#xa0;al. Chronic kidney disease and the gut microbiome. Am J Physiol Renal Physiol 2019; 316: F1211&#x2010;F1217.</Citation></Reference><Reference><Citation>Pergolizzi J, LeQuang JAK, Breve F, et&#xa0;al. Exploring the implications of new&#x2010;onset diabetes in COVID&#x2010;19: a narrative review. Cureus 2023; 15: e33319.</Citation></Reference><Reference><Citation>Cortes GM, Marcialis MA, Bardanzellu F, et&#xa0;al. Inflammatory bowel disease and COVID&#x2010;19: how microbiomics and metabolomics depict two sides of the same coin. Front Microbiol 2022; 13: 856165.</Citation></Reference><Reference><Citation>Assante G, Williams R, Youngson NA. Is the increased risk for MAFLD patients to develop severe COVID&#x2010;19 linked to perturbation of the gut&#x2010;liver axis? J Hepatol 2021; 74: 487&#x2010;488.</Citation></Reference><Reference><Citation>Guarnieri JW, Dybas JM, Fazelinia H, et&#xa0;al. Core mitochondrial genes are down&#x2010;regulated during SARS&#x2010;CoV&#x2010;2 infection of rodent and human hosts. Sci Transl Med 2023; 15: eabq1533.</Citation></Reference><Reference><Citation>Cortese M, Lee JY, Cerikan B, et&#xa0;al. Integrative imaging reveals SARS&#x2010;CoV&#x2010;2&#x2010;induced reshaping of subcellular morphologies. Cell Host Microbe 2020; 28: 853&#x2010;866.</Citation></Reference><Reference><Citation>Motta CS, Torices S, da Rosa BG, et&#xa0;al. Human brain microvascular endothelial cells exposure to SARS&#x2010;CoV&#x2010;2 leads to inflammatory activation through NF&#x2010;&#x3ba;B non&#x2010;canonical pathway and mitochondrial remodeling. Viruses 2023; 15: 745.</Citation></Reference><Reference><Citation>Mando C, Savasi VM, Anelli GM, et&#xa0;al. Mitochondrial and oxidative unbalance in placentas from mothers with SARS&#x2010;CoV&#x2010;2 infection. Antioxidants (Basel) 2021; 10: 1517.</Citation></Reference><Reference><Citation>Lai AL, Freed JH. SARS&#x2010;CoV&#x2010;2 fusion peptide has a greater membrane perturbating effect than SARS&#x2010;CoV with highly specific dependence on Ca2. J Mol Biol 2021; 433: 166946.</Citation></Reference><Reference><Citation>Wood E, Hall KH, Tate W. Role of mitochondria, oxidative stress and the response to antioxidants in myalgic encephalomyelitis/chronic fatigue syndrome: a possible approach to SARS&#x2010;CoV&#x2010;2 &#x201c;long&#x2010;haulers&#x201d;? Chronic Dis Transl Med 2021; 7: 14&#x2010;26.</Citation></Reference><Reference><Citation>Vernon SD, Whistler T, Cameron B, et&#xa0;al. Preliminary evidence of mitochondrial dysfunction associated with post&#x2010;infective fatigue after acute infection with Epstein Barr virus. BMC Infect Dis 2006; 6: 15.</Citation></Reference><Reference><Citation>Laura M, Sarah W, Benjamin G, et&#xa0;al. Plasma mediators in patients with severe COVID&#x2010;19 cause lung endothelial barrier failure. Eur&#xa0;Respir&#xa0;J 2021; 57: 2002384.</Citation></Reference><Reference><Citation>Yong SJ. Long COVID or post&#x2010;COVID&#x2010;19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond) 2021; 53: 737&#x2010;754.</Citation></Reference><Reference><Citation>Conway EM, Mackman N, Warren RQ, et&#xa0;al. Understanding COVID&#x2010;19&#x2010;associated coagulopathy. Nat Rev Immunol 2022; 22: 639&#x2010;649.</Citation></Reference><Reference><Citation>Wu C, Lu W, Zhang Y, et&#xa0;al. Inflammasome activation triggers blood clotting and host death through pyroptosis. Immunity 2019; 50: 1401&#x2010;1411.</Citation></Reference><Reference><Citation>Lazzaroni MG, Piantoni S, Masneri S, et&#xa0;al. Coagulation dysfunction in COVID&#x2010;19: the interplay between inflammation, viral infection and the coagulation system. Blood Rev 2021; 46: 100745.</Citation></Reference><Reference><Citation>Haffke M, Freitag H, Rudolf G, et&#xa0;al. Endothelial dysfunction and altered endothelial biomarkers in patients with post&#x2010;COVID&#x2010;19 syndrome and chronic fatigue syndrome (ME/CFS). J Transl Med 2022; 20: 138.</Citation></Reference><Reference><Citation>&#xd8;stergaard L. SARS CoV&#x2010;2 related microvascular damage and symptoms during and after COVID&#x2010;19: consequences of capillary transit&#x2010;time changes, tissue hypoxia and inflammation. Physiol Rep 2021; 9: e14726.</Citation></Reference><Reference><Citation>Swank Z, Senussi Y, Manickas&#x2010;Hill Z, et&#xa0;al. Persistent circulating severe acute respiratory&#xa0;syndrome coronavirus 2 spike is associated with post&#x2010;acute coronavirus disease 2019 sequelae. Clin Infect Dis 2023; 76: e487&#x2010;e490.</Citation></Reference><Reference><Citation>Lei Y, Zhang J, Schiavon CR, et&#xa0;al. SARS&#x2010;CoV&#x2010;2 spike protein impairs endothelial function via downregulation of ACE2. Circ Res 2021; 128: 1323&#x2010;1326.</Citation></Reference><Reference><Citation>Evans PC, Rainger GE, Mason JC, et&#xa0;al. Endothelial dysfunction in COVID&#x2010;19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science. Cardiovasc Res 2020; 116: 2177&#x2010;2184.</Citation></Reference><Reference><Citation>Kostov K. The causal relationship between endothelin&#x2010;1 and hypertension: focusing on endothelial dysfunction, arterial stiffness, vascular remodeling, and blood pressure regulation. Life (Basel) 2021; 11: 986.</Citation></Reference><Reference><Citation>Charfeddine S, Ibn Hadj Amor H, Jdidi J, et&#xa0;al. Long COVID 19 syndrome: is it related to microcirculation and endothelial dysfunction? Insights from TUN&#x2010;EndCOV study. Front Cardiovasc Med 2021; 8: 745758.</Citation></Reference><Reference><Citation>Kuchler T, Gunthner R, Ribeiro A, et&#xa0;al. Persistent endothelial dysfunction in post&#x2010;COVID&#x2010;19 syndrome and its associations with symptom severity and chronic inflammation. Angiogenesis 2023; 26: 547&#x2010;563.</Citation></Reference><Reference><Citation>Frishberg A, Kooistra E, Nuesch&#x2010;Germano M, et&#xa0;al. Mature neutrophils and a NF&#x2010;&#x3ba;B&#x2010;to&#x2010;IFN transition determine the unifying disease recovery dynamics in COVID&#x2010;19. Cell Rep Med 2022; 3: 100652.</Citation></Reference><Reference><Citation>Jukema BN, Smit K, Hopman MTE, et&#xa0;al. Neutrophil and eosinophil responses remain abnormal for several months in primary care patients with COVID&#x2010;19 disease. Front Allergy 2022; 3: 942699.</Citation></Reference><Reference><Citation>Pisareva E, Badiou S, Mihalovi&#x10d;ov&#xe1; L, et&#xa0;al. Persistence of neutrophil extracellular traps and anticardiolipin auto&#x2010;antibodies in post&#x2010;acute phase COVID&#x2010;19 patients. J Med Virol 2023; 95: e28209.</Citation></Reference><Reference><Citation>Weinstock LB, Brook JB, Walters AS, et&#xa0;al. Mast cell activation symptoms are prevalent in long&#x2010;COVID. Int J Infect Dis 2021; 112: 217&#x2010;226.</Citation></Reference><Reference><Citation>Krysko O, Bourne JH, Kondakova E, et&#xa0;al. Severity of SARS&#x2010;CoV&#x2010;2 infection is associated with high numbers of alveolar mast cells and their degranulation. Front Immunol 2022; 13: 968981.</Citation></Reference><Reference><Citation>Patterson BK, Francisco EB, Yogendra R, et&#xa0;al. Persistence of SARS CoV&#x2010;2 S1 protein in CD16+ monocytes in post&#x2010;acute sequelae of COVID&#x2010;19 (PASC) up to 15 months post&#x2010;infection. Front Immunol 2021; 12: 746021.</Citation></Reference><Reference><Citation>Ryan FJ, Hope CM, Masavuli MG, et&#xa0;al. Long&#x2010;term perturbation of the peripheral immune system months after SARS&#x2010;CoV&#x2010;2 infection. BMC Med 2022; 20: 26.</Citation></Reference><Reference><Citation>Peluso MJ, Deitchman AN, Torres L, et&#xa0;al. Long&#x2010;term SARS&#x2010;CoV&#x2010;2&#x2010;specific immune and inflammatory responses in individuals recovering from COVID&#x2010;19 with and without post&#x2010;acute symptoms. Cell Rep 2021; 36: 109518.</Citation></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, et&#xa0;al. Immunological dysfunction persists for 8 months following initial mild&#x2010;to&#x2010;moderate SARS&#x2010;CoV&#x2010;2 infection. Nat Immunol 2022; 23: 210&#x2010;216.</Citation></Reference><Reference><Citation>Wiech M, Chroscicki P, Swatler J, et&#xa0;al. Remodeling of T cell dynamics during long COVID is dependent on severity of SARS&#x2010;CoV&#x2010;2 infection. Front Immunol 2022; 13: 886431.</Citation></Reference><Reference><Citation>Kim JYH, Ragusa M, Tortosa F, et&#xa0;al. Viral reactivations and co&#x2010;infections in COVID&#x2010;19 patients: a systematic review. BMC Infect Dis 2023; 23: 259.</Citation></Reference><Reference><Citation>Santopaolo M, Gregorova M, Hamilton F, et&#xa0;al. Prolonged T&#x2010;cell activation and long COVID symptoms independently associate with severe&#xa0;COVID&#x2010;19 at 3 months. Elife 2023; 12: e85009.</Citation></Reference><Reference><Citation>Bull&#x2010;Otterson L, K SBSST, Gray BSAS, Harris AM. Post&#x2010;COVID conditions among adult COVID&#x2010;19 survivors aged 18&#x2013;64 and &#x2265;&#x2009;65 years &#x2014; United States, March 2020 &#x2013; November 2021. MMWR Morb Mortal Wkly Rep 2022; 71: 713&#x2010;717.</Citation></Reference><Reference><Citation>Varnai R, Molnar T, Zavori L, et&#xa0;al. Serum level of anti&#x2010;nucleocapsid, but not anti&#x2010;spike antibody, is associated with improvement of long COVID symptoms. Vaccines (Basel) 2022; 10: 165.</Citation></Reference><Reference><Citation>Augustin M, Schommers P, Stecher M, et&#xa0;al. Post&#x2010;COVID syndrome in non&#x2010;hospitalised patients with COVID&#x2010;19: a longitudinal prospective cohort study. Lancet Reg Health Eur 2021; 6: 100122.</Citation></Reference><Reference><Citation>Fedorchenko Y, Zimba O. Long COVID in autoimmune rheumatic diseases. Rheumatol Int 2023; 43: 1197&#x2010;1207.</Citation></Reference><Reference><Citation>Grubi&#x161;i&#x107; B, &#x160;vitek L, Ormanac K, et&#xa0;al. Molecular mechanisms responsible for diabetogenic effects of COVID&#x2010;19 infection&#x2010;induction of autoimmune dysregulation and metabolic disturbances. Int J Mol Sci 2023; 24: 11576.</Citation></Reference><Reference><Citation>Zhang T, Mei Q, Zhang Z, et&#xa0;al. Risk for newly diagnosed diabetes after COVID&#x2010;19: a systematic review and meta&#x2010;analysis. BMC Med 2022; 20: 444.</Citation></Reference><Reference><Citation>Wu CT, Lidsky PV, Xiao Y, et&#xa0;al. SARS&#x2010;CoV&#x2010;2 infects human pancreatic &#x3b2; cells and elicits &#x3b2; cell impairment. Cell Metab 2021; 33: 1565&#x2010;1576.</Citation></Reference><Reference><Citation>Baimukhamedov C, Barskova T, Matucci&#x2010;Cerinic M. Arthritis after SARS&#x2010;CoV&#x2010;2 infection. Lancet Rheumatol 2021; 3: e324&#x2010;e325.</Citation></Reference><Reference><Citation>Ramachandran L, Dontaraju VS, Troyer J, Sahota J. New onset systemic lupus erythematosus after COVID&#x2010;19 infection: a case report. AME Case Rep 2022; 6: 14.</Citation></Reference><Reference><Citation>Bastard P, Gervais A, Le Voyer T, et&#xa0;al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID&#x2010;19 deaths. Sci Immunol 2021; 6: eabl4340.</Citation></Reference><Reference><Citation>Matyushkina D, Shokina V, Tikhonova P, et&#xa0;al. Autoimmune effect of antibodies against the SARS&#x2010;CoV&#x2010;2 nucleoprotein. Viruses 2022; 14: 1141.</Citation></Reference><Reference><Citation>Bastard P, Rosen LB, Zhang Q, et&#xa0;al. Autoantibodies against type I IFNs in patients with life&#x2010;threatening COVID&#x2010;19. Science 2020; 370: eabd4585.</Citation></Reference><Reference><Citation>Solanich X, Rigo&#x2010;Bonnin R, Gumucio VD, et&#xa0;al. Pre&#x2010;existing autoantibodies neutralizing high concentrations of type I Interferons in almost 10% of COVID&#x2010;19 patients admitted to intensive care in Barcelona. J Clin Immunol 2021; 41: 1733&#x2010;1744.</Citation></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, et&#xa0;al. Multiple early factors anticipate post&#x2010;acute COVID&#x2010;19 sequelae. Cell 2022; 185: 881&#x2010;895.</Citation></Reference><Reference><Citation>Wang F, Ma Y, Xu S, et&#xa0;al. Prevalence and risk of COVID&#x2010;19 in patients with rheumatic diseases: a systematic review and meta&#x2010;analysis. Clin Rheumatol 2022; 41: 2213&#x2010;2223.</Citation></Reference><Reference><Citation>Panayiotis GV, Eleni M, Haris A, et&#xa0;al. Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID&#x2010;19. Ann Rheum Dis 2020; 79: 1661&#x2010;1663.</Citation></Reference><Reference><Citation>Klein J, Wood J, Jaycox J, et&#xa0;al. Distinguishing features of long COVID identified through immune profiling. Nature 2023; 623: 139&#x2010;148.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>